Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D., will present a corporate update at the 45th Annual Goldman Sachs Global Healthcare Conference in Miami Beach, FL, from June 10-13, 2024. The presentation is scheduled for June 12, 2024, at 2:40 p.m. ET. Investors will have the opportunity to participate in one-on-one meetings with the CEO. The presentation will be webcast.
- CEO Yuval Cohen, Ph.D., is set to present at a high-profile healthcare conference.
- Opportunity for one-on-one meetings with investors, potentially boosting investor confidence.
- Webcasting the presentation increases accessibility and investor reach.
- No specific financial or clinical updates were highlighted in the announcement.
- Potential for shareholder dilution if future funding or capital raising activities are discussed at the conference and perceived negatively.
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the 45th Annual Goldman Sachs Global Healthcare Conference to be held June 10-13, 2024 in Miami Beach, FL.
45th Annual Goldman Sachs Global Healthcare Conference
Format: Presentation and one-on-one investor meetings
Presentation Date: Wednesday, June 12, 2024
Presentation Time: 2:40 p.m. ET
Webcast: Click Here
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend," “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Sean.moran@corbuspharma.com
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
What is the date of Corbus Pharmaceuticals' presentation at the Goldman Sachs Global Healthcare Conference?
Where is Corbus Pharmaceuticals presenting its corporate update?
Who will present Corbus Pharmaceuticals' corporate update at the conference?
Will the Corbus Pharmaceuticals presentation be available online?
What is the ticker symbol for Corbus Pharmaceuticals?
